Are Semaglutide and Tirzepatide Peptides — and Does It Matter Clinically?

What does it actually mean to call these medicines peptides?

A peptide is simply a molecule built from amino acids joined in a chain, the same building blocks as proteins, just shorter. Your body makes peptides constantly; the ones relevant here are gut hormones released after eating. Semaglutide is a GLP-1 receptor agonist: it is a modified analogue of glucagon-like peptide-1, a natural hormone that signals fullness and blunts appetite. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning its peptide structure is engineered to activate two separate hormone receptors rather than one.

Both medicines are administered as injections precisely because peptides are broken down in the digestive tract before they can reach the bloodstream in useful quantities. The weekly injection format bypasses that problem. Wegovy tablets (oral semaglutide) solve this differently (co-formulated with an absorption enhancer that lets enough of the peptide cross the stomach wall) but even that approach only works because of tight rules about how and when the tablet is taken.

A question our prescribers hear most weeks is whether semaglutide or tirzepatide is the right choice, and the honest answer is that receptor count alone doesn't settle it; individual response, tolerability and your health history all feed into the clinical picture.

Where do their peptide structures diverge, and what follows from that difference?

Semaglutide (sold for weight management as Wegovy) acts on a single pathway: the GLP-1 receptor. That receptor is found in the brain, gut and pancreas. Activating it reduces hunger, slows the movement of food through the stomach and supports blood-sugar regulation. The clinical programme behind it is substantial: the STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

Tirzepatide (sold as Mounjaro) adds the GIP receptor to that picture. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone involved in energy storage and appetite regulation. Activating both receptors together produced larger average weight reductions in trials: the SURMOUNT-1 study reported reductions of around 20–21% at the 15mg dose. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks, as discussed in NICE's appraisal of tirzepatide (TA1026). The newer 7.2mg Wegovy dose narrows that gap considerably, with trials reporting around 20.7% average loss, worth knowing when comparing the two.

Neither result is a promise for any individual. Averages describe populations; your prescriber's job is to think about you specifically.

Does the peptide classification change which patients each medicine suits?

Not directly, eligibility turns on licensed indications, BMI thresholds and clinical history rather than on molecular type. Both carry a UK licence for weight management in adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Their peptide nature does create one practical consideration worth flagging: because they slow gastric emptying, both medicines can affect the absorption of other oral drugs taken at the same time, including oral contraceptives, something a prescriber reviews during assessment.

One more distinction: Ozempic is also semaglutide, but it holds a UK licence for type 2 diabetes management, not weight loss, the peptide is identical, the indication is not. Similarly, Rybelsus (oral semaglutide at diabetes doses) is not a weight-loss medicine under UK licensing. If you have arrived here because of those names, the weight-management routes in the UK are Wegovy (semaglutide injection or tablet) and Mounjaro (tirzepatide injection). You can read a fuller side-by-side on the Wegovy versus Mounjaro page, or explore a detailed comparison of semaglutide and tirzepatide if you want the numbers laid out more fully.

Semaglutide vs tirzepatide at a glance

Trial figures are averages from controlled studies alongside diet and activity support; individual results vary. Sources: NEJM STEP 1; NICE TA1026.

Which of these peptide medicines is the right fit for you is a clinical decision, not a chemistry one. Our prescribers work through the relevant factors with you (health history, current medicines, your preferences about injections versus tablets) during the consultation. If you are curious about whether tirzepatide and semaglutide can be combined or used together, that page covers what the evidence says, and the tirzepatide after semaglutide page covers what that switching process typically involves. Patients on Mounjaro sometimes also ask about facial fat loss associated with tirzepatide and similar medicines, which is worth reading if that is something on your mind. For anything specific to your situation, start your free consultation and a prescriber will work through it with you the same day.